MEDBOT™

Shanghai MicroPort MedBot (Group) Co., Ltd.

上海微创医疗机器人(集团)股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2252)

PROPOSED AMENDMENT TO THE ARTICLES OF ASSOCIATION AND PROPOSED APPOINTMENT OF EXECUTIVE DIRECTOR

Proposed Amendment to the Articles of Association

The board of directors of Shanghai MicroPort MedBot (Group) Co., Ltd. (the "**Company**" and its subsidiaries, collectively the "**Group**") proposed that, in order to optimise the composition of the board of directors of the Company (the "**Board**"), the number of Board seats specified in the articles of association of the Company (the "**Articles of Association**") be increased from 8 to 9 (the "**Proposed Amendment to the Articles of Association**").

The Proposed Amendment to the Articles of Association shall be considered and approved by the shareholders of the Company at the upcoming annual general meeting of the Company (the "**AGM**"), and will become effective upon approval by the shareholders of the Company at the AGM.

Proposed Appointment of Executive Director

The Board further announces that, as considered and approved by the Board, subject to the consideration and approval of the resolution in relation to the Proposed Amendment of the Articles of Association by the shareholders of the Company at the AGM, Mr. Liu Yu ("**Mr. Liu**") has been nominated as an executive director of the Company with the term of office of not more than three years commencing from the date of which approval is obtained at the AGM until the expiry of the term of office of the second session of the Board. The proposed appointment of Mr. Liu as an executive director of the Company is subject to the consideration and approval by the shareholders of the Company at the AGM.

The biographical details of Mr. Liu are as follows:

Mr. Liu Yu (劉雨), aged 55, joined the Group on 1 December 2020 as the chief commercial officer and vice president. From March 2021 to May 2022, Mr. Liu served as the chief commercial officer and senior vice president of the Group, and since June 2022, he has been serving as the chief commercial officer and executive vice president of the Group. Mr. Liu is primarily responsible for sales and marketing, and clinical and medical affairs of the Group. Mr. Liu has also been serving as the executive director and manager of 1.1 Medical (Beijing) Health Technology Co., Ltd. (易達醫（北京）健康科技有限公司) since September 2020, where he is primarily responsible for its operations and management.

Mr. Liu has over 30 years of experience in pharmaceuticals and medical devices. Prior to joining the Group, Mr. Liu joined the Beijing office of American Medtronic China Co., Ltd. (美國美敦力中國有限責任公司北京辦事處), a medical technology company, in November 2001. In April 2003, Mr. Liu join Chindex (Beijing) International Trade Co., Ltd. (美中互利北京國際貿易有限公司) ("**Chindex Beijing**"), a company principally engaged in provision of medical and health services and distribution of medical devices, as a north regional manager primarily responsible for product management. Mr. Liu then joined the Beijing office of Germany BrainLAB Co., Ltd. (德國博醫來公司北京代表處), a company principally engaged in surgical software and hardware development, as a sales manager until October 2006 where he was primarily responsible for its marketing and sales. He also served as the chief representative of the Beijing branch of Canadian IMRIS Co., Ltd. (加拿大醫美瑞有限公司北京代表處), a company principally engaged in medical device management, where he was primarily responsible for overseeing its daily operation. From July 2008 to 2017, Mr. Liu served as chief operating officer and senior vice president of Chindex Beijing and Chindex Medical Limited (美中互利醫療有限公司), a distribution partner for Intuitive Surgical's da Vinci Surgical Systems in China. From January 2017 to August 2019, Mr. Liu successively served as a senior vice president and chief operation officer of the medical device department of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (上海復星醫藥(集團)股份有限公司), a pharmaceutical company whose shares are listed on The Stock Exchange of Hong Kong Limited (stock code: 2196), and a senior vice president and chief commercial officer of Intuitive Surgical-Fosun Medical Technology (Shanghai) Co., Ltd. (直觀復星醫療器械技術(上海)有限公司), a company principally engaged in the medical device industry, where Mr. Liu was primarily responsible for managing the sales and marketing of its da Vinci surgical robot. From September 2019 to June 2020, Mr. Liu served as the chief executive officer of Shanghai Ruidao Medical Technology Co., Ltd. (上海睿刀醫療科技有限公司), a company principally engaged in production of medical devices, where he was primarily responsible for its overall operations and management.

Mr. Liu obtained a bachelor's degree in mechanical instruments engineering from Tianjin University of Technology and a master's degree in economic management from Tsinghua University.

Save as disclosed above, (i) Mr. Liu does not hold any other positions with the Company and/or any of its subsidiaries; (ii) Mr. Liu does not, nor did he in the past three years, hold any directorships in other public companies the securities of which are listed on any securities market in Hong Kong or overseas; (iii) Mr. Liu does not have any relationships with any directors, supervisors, senior management, substantial shareholders or controlling shareholders of the Company; and (iv) Mr. Liu does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

As at the date of this announcement, there are no other matters relating to the proposed appointment of Mr. Liu that are required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and there are no other matters relating to the proposed appointment of Mr. Liu that need to be brought to the attention of the shareholders of the Company.

Subject to the consideration and approval of the resolution in relation to the Proposed Amendment to the Articles of Association by the shareholders of the Company at the AGM, upon the proposed appointment of Mr. Liu being approved by the shareholders of the Company, he will enter into a service contract with the Company for a term of not more than three years commencing from the date of being elected at the AGM until the end of the second session of the Board. Pursuant to the service contract and during his tenure as a senior management of the Company, Mr. Liu will not receive any remuneration from the Group for his office as an executive director and solely receives remuneration from the Group in his capacity as a senior management.

A circular, containing, among other things, details of the above resolutions will be despatched to the shareholders of the Company in due course.

By Order of the Board
Shanghai MicroPort MedBot (Group) Co., Ltd.
Mr. Sun Hongbin
Chairman

Shanghai, China, 27 March 2025

As at the date of this announcement, the executive directors are Dr. He Chao and Ms. Fang Cong, the non-executive directors are Mr. Sun Hongbin, Mr. Chen Xinxing and Mr. Chen Chen, and the independent non-executive directors are Dr. Li Minghua, Mr. Yao Haisong and Mr. Chung Wai Man.